CA3162626A1 - Aqueous suspension composition containing sirolimus or salt thereof - Google Patents
Aqueous suspension composition containing sirolimus or salt thereofInfo
- Publication number
- CA3162626A1 CA3162626A1 CA3162626A CA3162626A CA3162626A1 CA 3162626 A1 CA3162626 A1 CA 3162626A1 CA 3162626 A CA3162626 A CA 3162626A CA 3162626 A CA3162626 A CA 3162626A CA 3162626 A1 CA3162626 A1 CA 3162626A1
- Authority
- CA
- Canada
- Prior art keywords
- aqueous suspension
- sirolimus
- suspension composition
- salt
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019237226 | 2019-12-26 | ||
| JP2019-237226 | 2019-12-26 | ||
| PCT/JP2020/048738 WO2021132565A1 (ja) | 2019-12-26 | 2020-12-25 | シロリムスまたはその塩を含有する水性懸濁組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3162626A1 true CA3162626A1 (en) | 2021-07-01 |
Family
ID=76575568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3162626A Pending CA3162626A1 (en) | 2019-12-26 | 2020-12-25 | Aqueous suspension composition containing sirolimus or salt thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230055121A1 (https=) |
| EP (1) | EP4082544A4 (https=) |
| JP (2) | JP7682103B2 (https=) |
| KR (1) | KR20220122612A (https=) |
| CN (2) | CN118340726A (https=) |
| AU (1) | AU2020411442B2 (https=) |
| CA (1) | CA3162626A1 (https=) |
| TW (1) | TWI871406B (https=) |
| WO (1) | WO2021132565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942607A (zh) * | 2023-01-13 | 2023-10-27 | 杭州微致生物科技有限公司 | 一种西罗莫司混悬液 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| ES2507078T3 (es) * | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| CN105073112B (zh) | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
| JP6279395B2 (ja) * | 2014-05-01 | 2018-02-14 | 東亜薬品株式会社 | ブリンゾラミド懸濁性点眼液組成物の製造方法 |
| CN105833344B (zh) * | 2016-04-26 | 2019-04-26 | 青岛慧生惠众生物科技有限公司 | 一种可注射水凝胶在制备眼内填充物中的应用 |
| CN106420607B (zh) | 2016-11-02 | 2019-06-28 | 北京诺康达医药科技股份有限公司 | 一种西罗莫司纳米混悬剂及其制备方法 |
| EP3565520B1 (en) * | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| CN107334734B (zh) | 2017-07-10 | 2020-03-17 | 浙江大学 | 一种西罗莫司或其衍生物的眼用制剂 |
| US20200261427A1 (en) * | 2019-02-20 | 2020-08-20 | Al Therapeutics, Inc. | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders |
-
2020
- 2020-12-25 US US17/784,327 patent/US20230055121A1/en active Pending
- 2020-12-25 WO PCT/JP2020/048738 patent/WO2021132565A1/ja not_active Ceased
- 2020-12-25 CA CA3162626A patent/CA3162626A1/en active Pending
- 2020-12-25 JP JP2021567672A patent/JP7682103B2/ja active Active
- 2020-12-25 CN CN202410500671.8A patent/CN118340726A/zh active Pending
- 2020-12-25 EP EP20905210.9A patent/EP4082544A4/en active Pending
- 2020-12-25 AU AU2020411442A patent/AU2020411442B2/en active Active
- 2020-12-25 KR KR1020227018715A patent/KR20220122612A/ko not_active Ceased
- 2020-12-25 CN CN202080089390.8A patent/CN114845714B/zh active Active
- 2020-12-25 TW TW109146288A patent/TWI871406B/zh active
-
2025
- 2025-05-13 JP JP2025080159A patent/JP2025111828A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021132565A1 (ja) | 2021-07-01 |
| TWI871406B (zh) | 2025-02-01 |
| AU2020411442B2 (en) | 2026-02-12 |
| KR20220122612A (ko) | 2022-09-02 |
| JP7682103B2 (ja) | 2025-05-23 |
| AU2020411442A1 (en) | 2022-06-23 |
| JPWO2021132565A1 (https=) | 2021-07-01 |
| US20230055121A1 (en) | 2023-02-23 |
| CN118340726A (zh) | 2024-07-16 |
| EP4082544A4 (en) | 2024-01-10 |
| JP2025111828A (ja) | 2025-07-30 |
| TW202135806A (zh) | 2021-10-01 |
| CN114845714A (zh) | 2022-08-02 |
| CN114845714B (zh) | 2024-05-14 |
| EP4082544A1 (en) | 2022-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11826429B2 (en) | Pharmaceutical composition comprising brinzolamide | |
| EA034839B1 (ru) | Офтальмологический раствор | |
| US20240390515A1 (en) | Multidose ophthalmic compositions | |
| KR20160060656A (ko) | 폴리에틸렌글리콜 함유 조성물 | |
| JP2025111828A (ja) | シロリムスまたはその塩を含有する水性懸濁組成物 | |
| US11331311B2 (en) | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | |
| US12600702B2 (en) | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof | |
| WO2018235935A1 (ja) | 水溶性粘稠化剤を含有する医薬組成物 | |
| RU2842860C1 (ru) | Водная суспензионная композиция, содержащая сиролимус или его соль | |
| KR20230107624A (ko) | 레보플록사신 및 케토롤락을 함유하는 안과용 조성물, 이의 제조 방법 및 용도 | |
| TWI773778B (zh) | 含有水溶性黏稠化劑之醫藥組合物 | |
| KR20170129832A (ko) | 폴리펩티드를 함유하는 의약 조성물 | |
| EA051764B1 (ru) | Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение | |
| HK40006512A (en) | Medicinal composition | |
| NZ619229B2 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| NZ619229A (en) | Topical ophthalmological pharmaceutical composition containing regorafenib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241128 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241128 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250428 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251125 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260225 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260226 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260226 |